Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma von Martin, Thomas, Strickland, Stephen, Glenn, Martha, Charpentier, Eric, Guillemin, Hélène, Hsu, Karl, Mikhael, Joseph

Volltext

Interplay of Pu.1 and Gata1 Determines Myelo-Erythroid Progenitor Cell Fate in Zebrafish von Rhodes, Jennifer, Hagen, Andreas, Hsu, Karl, Deng, Min, Liu, Ting Xi, Look, A.Thomas, Kanki, John P.

Volltext

Making waves in cancer research: new models in the zebrafish von Berghmans, Stephane, Jette, Cicely, Langenau, David, Hsu, Karl, Stewart, Rodney, Look, Thomas, Kanki, John P

Volltext

Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment von Bonnevaux, Hélène, Guerif, Stephane, Albrecht, Jana, Jouannot, Erwan, De Gallier, Thibaud, Beil, Christian, Lange, Christian, Leuschner, Wulf Dirk, Schneider, Marion, Lemoine, Cendrine, Caron, Anne, Amara, Céline, Barrière, Cédric, Siavellis, Justine, Bardet, Valérie, Luna, Ernesto, Agrawal, Pankaj, Drake, Donald R., Rao, Ercole, Wonerow, Peter, Carrez, Chantal, Blanc, Véronique, Hsu, Karl, Wiederschain, Dmitri, Fraenkel, Paula G., Virone-Oddos, Angéla

Volltext

A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma von Martin, Thomas G., Hsu, Karl, Strickland, Stephen Anthony, Glenn, Martha Jane, Mikhael, Joseph, Charpentier, Eric

Volltext

Knockdown of Zebrafish Fancd2 Causes Developmental Abnormalities via p53-Dependent Apoptosis von Liu, Ting Xi, Howlett, Niall G., Deng, Min, Langenau, David M., Hsu, Karl, Rhodes, Jennifer, Kanki, John P., D'Andrea, Alan D., Look, A.Thomas

Volltext

The role and regulation of friend of GATA-1 (FOG-1) during blood development in the zebrafish von Amigo, Julio D., Ackermann, Gabriele E., Cope, John J., Yu, Ming, Cooney, Jeffrey D., Ma, Dongdong, Langer, Nathaniel B., Shafizadeh, Ebrahim, Shaw, George C., Horsely, Wyatt, Trede, Nikolaus S., Davidson, Alan J., Barut, Bruce A., Zhou, Yi, Wojiski, Sarah A., Traver, David, Moran, Tyler B., Kourkoulis, George, Hsu, Karl, Kanki, John P., Shah, Dhvanit I., Lin, Hui Feng, Handin, Robert I., Cantor, Alan B., Paw, Barry H.

Volltext

A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours von de Jonge, Maja, de Weger, Vincent A, Dickson, Mark A, Langenberg, Marlies, Le Cesne, Axel, Wagner, Andrew J, Hsu, Karl, Zheng, Wei, Macé, Sandrine, Tuffal, Gilles, Thomas, Koruth, Schellens, Jan H.M

Volltext

Preliminary results of a phase 1/2, first-in-human, open-label, dose escalation study of ZL-1211 (anti-Claudin 18.2 mAb) in patients with unresectable or metastatic solid tumors von Sharma, Sunil, Starodub, Alexander, Xu, Nong, Chaudhry, Arvind, Sun, Meili, Pelster, Meredith, Fu, Yinjia, Zhang, Xinyu, Huang, Zhao, Liu, Wenyu, Hsu, Karl

Volltext

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours von de Weger, Vincent A., de Jonge, Maja, Langenberg, Marlies H. G., Schellens, Jan H. M., Lolkema, Martijn, Varga, Andrea, Demers, Brigitte, Thomas, Koruth, Hsu, Karl, Tuffal, Gilles, Goodstal, Samantha, Macé, Sandrine, Deutsch, Eric

Volltext

Challenges to Using Big Data in Cancer von Sweeney, Shawn M, Hamadeh, Hisham K, Abrams, Natalie, Adam, Stacey J, Brenner, Sara, Connors, Dana E, Davis, Gerard J, Fiore, Louis, Gawel, Susan H, Grossman, Robert L, Hanlon, Sean E, Hsu, Karl, Kelloff, Gary J, Kirsch, Ilan R, Louv, Bill, McGraw, Deven, Meng, Frank, Milgram, Daniel, Miller, Robert S, Morgan, Emily, Mukundan, Lata, O'Brien, Thomas, Robbins, Paul, Rubin, Eric H, Rubinstein, Wendy S, Salmi, Liz, Schaller, Teilo, Shi, George, Sigman, Caroline C, Srivastava, Sudhir

Volltext

Abstract 498: ZL-1201, a differentiated CD47 therapeutic antibody with improved hematological safety profile von Wan, Bing, Fang, Xu, Li, Shou, Shi, Wenhua, Li, Holly, Bellovin, David, Wang, Lei, Zhu, Yusong, Lin, Yuan, Qi, Shali, Yin, Sophia, Tao, Frank, Kang, Lishan, Kabbarah, Omar, Zhou, Haiying, Veiby, Petter, Yan, James, Hsu, Karl

Volltext

Abstract 1203: ZL-1211 exhibits broad anti-tumor activity in CLDN18.2 high- and low-expressing models von Konno, Hiroyasu, Li, Yong, Dai, Xinchuan, Sun, Bee, Shi, Wenhua, Chen, Min, Li, Wenying, Li, Shou, Kang, Lishan, Li, Holly, Tao, Frank, Yin, Sophia, Wang, Bingbing, Shan, Lishen, Wan, Bing, Veiby, Petter, Yan, James, Hsu, Karl, Bellovin, David, Kabbarah, Omar

Volltext

A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tum... von ATZORI, Francesco, TABERNERO, Josep, DI COSIMO, Serena, BROWN, Holly, CLARK, Jason, HARDWICK, James S, BECKMAN, Robert A, HANLEY, William D, HSU, Karl, CALVO, Emiliano, ROSELLO, Susana, LANGDON, Ronald B, CERVANTES, Andrés, BASELGA, José, PRUDKIN, Ludmila, ANDREU, Jordi, RODRIGUEZ-BRAUN, Edith, DOMINGO, Amparo, GUIJARRO, Jorge, GAMEZ, Cristina, RODON, Jordi

Volltext

Case Studies for Overcoming Challenges in Using Big Data in Cancer von Sweeney, Shawn M, Hamadeh, Hisham K, Abrams, Natalie, Adam, Stacey J, Brenner, Sara, Connors, Dana E, Davis, Gerard J, Fiore, Louis D, Gawel, Susan H, Grossman, Robert L, Hanlon, Sean E, Hsu, Karl, Kelloff, Gary J, Kirsch, Ilan R, Louv, Bill, McGraw, Deven, Meng, Frank, Milgram, Daniel, Miller, Robert S, Morgan, Emily, Mukundan, Lata, O'Brien, Thomas, Robbins, Paul, Rubin, Eric H, Rubinstein, Wendy S, Salmi, Liz, Schaller, Teilo H, Shi, George, Sigman, Caroline C, Srivastava, Sudhir

Volltext

Abstract 4531: Clinical translation of biomarkers for ZL-1211, an anti-CLDN18.2 antibody, in patients with advanced solid tumors from a phase I dose-escalation study von Luo, Zhen, Wang, Xiao, Zeng, Xuehuo, Yi, Jiaqing, Burns, Tegan, Liu, Herman, Zhang, Xinyu, Liu, Wenyu, Hsu, Karl, Gong, Hua

Volltext

Antibody-based therapy for solid tumors von Yan, Li, Hsu, Karl, Beckman, Robert A

Volltext

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours von de Weger, Vincent A, de Jonge, Maja, Langenberg, Marlies H G, Schellens, Jan H M, Lolkema, Martijn, Varga, Andrea, Demers, Brigitte, Thomas, Koruth, Hsu, Karl, Tuffal, Gilles, Goodstal, Samantha, Macé, Sandrine, Deutsch, Eric

Volltext

Chromosome 5q deletion and epigenetic suppression of the gene encoding α-catenin ( CTNNA1 ) in myeloid cell transformation von Look, A Thomas, Liu, Ting Xi, Becker, Michael W, Jelinek, Jaroslav, Wu, Wen-Shu, Deng, Min, Mikhalkevich, Natallia, Hsu, Karl, Bloomfield, Clara D, Stone, Richard M, DeAngelo, Daniel J, Galinsky, Ilene A, Issa, Jean-Pierre, Clarke, Michael F

Volltext

Abstract 3425: The CD47-targeting antibody ZL-1201 enhances anti-tumor activity of standard of care therapeutic antibodies by promoting phagocytosis in hematologic and solid tumor... von Cao, Anthony, Yi, Jiaqing, Wu, Renyi, Szeto, Christopher, Ye, Quiping, Wan, Bing, Hsu, Karl, Kabbarah, Omar, Zhou, Haiying

Volltext